NCT04493619View on ClinicalTrials.gov

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

April 25, 2022

Study Completion Date

April 25, 2022

Conditions
Gynecologic NeoplasmsEpithelial Ovarian Cancer
Interventions
DRUG

PLX2853

PLX2853 tablets

DRUG

Carboplatin

Carboplatin IV injection, 5 mg•min/mL

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

22031

Virginia Cancer Specialists, PC, Fairfax

22908

University of Virginia Health Systems, Charlottesville

37203

Tennessee Oncology / Sarah Cannon, Nashville

73104

University of Oklahoma - Stephenson Cancer Center, Oklahoma City

98109

University of Washington / Seattle Cancer Care Alliance, Seattle

05841

The University of Chicago Medical Center, Chicago

02114

Massachusetts General Hospital, Boston

Unknown

Princess Margaret Cancer Centre, Toronto

Sponsors

Lead Sponsor

Opna Bio LLC
All Listed Sponsors
lead

Opna Bio LLC

INDUSTRY

NCT04493619 - PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter